Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimers Disease: early-phase trial registry
35 of 150 indexed Alzheimers Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #78 of 28,707 conditions by registered trial count.
150 US clinical trials · 35 currently recruiting · #78 of 28,707 conditions by registered trial count
Alzheimers Disease: 150 US clinical trials tracked, 35 recruiting.
Alzheimers Disease is the subject of 150 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 76 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 8 of these trials.
Enrollment posture brief
Registry condition alzheimers-disease
OPEN 35 | RECR 23% | LATE 25 | EARLY 76 | RANK #78 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus (23% recruiting · 210 trials)
Alzheimers Disease lists 35 open slots (23% of 150 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimers Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimers Disease is recruiting below its size-band peers.
35 of 150 indexed trials (23.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimers Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 8 of 150 trials (5.3%). 90 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimers Disease enrolment sits around 105 participants.
Median target enrolment is 105 among the 148 trials that report a genuine target (sentinel values excluded). 70 of those (47.3%) plan for fewer than 100 participants.
-
Alzheimers Disease research is mostly interventional.
123 interventional and 27 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
150 total, page 1 of 3
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
Banner Health
NCT02022943
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
NCT07177352
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
Eisai Korea
NCT06810960
Retinal Imaging in Neurodegenerative Disease
Duke University
NCT03233646
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
GAP Innovations, PBC
NCT06584357
Wake Forest Alzheimer's Disease Clinical Core
Wake Forest University Health Sciences
NCT03140865
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche
NCT07170150
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche
NCT07169578
Dominantly Inherited Alzheimer Network (DIAN)
Washington University School of Medicine
NCT00869817
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
NCT06976216
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
NCT06976203
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
Novartis Pharmaceuticals
NCT07094516
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine
NCT06647498
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine
NCT05552157
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Brigham and Women's Hospital
NCT02649985
Phosphorylated Tau Levels in Donated Blood
The University of Texas Health Science Center, Houston
NCT07157839
Open-label Extension Study in Participants With Early Alzheimer's Disease
GlaxoSmithKline
NCT07105709
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
National Institute of Mental Health (NIMH)
NCT04396873
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
AC Immune
NCT05462106
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
University of Pennsylvania
NCT05658913
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
University of Washington
NCT06411561
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
National Institute of Mental Health (NIMH)
NCT07169630
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Douglas Scharre
NCT03019757
University of Central Florida Music Study
University of Central Florida
NCT07306065
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
University of California, San Diego
NCT06548191
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
University of California, Los Angeles
NCT06597942
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Massachusetts Institute of Technology
NCT05655195
Pulsed Electromagnetic Field Treatment With Dementia Patients
Herrick Medical
NCT06862557
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Oregon Health and Science University
NCT05591027
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
Cedars-Sinai Medical Center
NCT07224607
Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's Patients
University of Arizona
NCT07303998
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Brigham and Women's Hospital
NCT06489548
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
Mark Tuszynski
NCT05040217
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
Emory University
NCT06484244
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
Pennington Biomedical Research Center
NCT07265323
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
Eisai Limited
NCT06043700
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company
NCT05463731
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company
NCT06653153
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company
NCT05738486
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Washington University School of Medicine
NCT01760005
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
GlaxoSmithKline
NCT06079190
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
Hoffmann-La Roche
NCT04639050
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Neurim Pharmaceuticals
NCT05267535
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Washington University School of Medicine
NCT05269394
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Eisai
NCT06602258
Tango for Alzheimer's Disease Patients' Caregivers
Emory University
NCT03269149
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Washington University School of Medicine
NCT06384573
Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study
American College of Radiology
NCT02420756
Ginkgo Biloba Prevention Trial in Older Individuals
National Center for Complementary and Integrative Health (NCCIH)
NCT00010803
Observational Study on Costs and Caregiver Burden in Alzheimer's Disease
AstraZeneca
NCT00698165
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 39 |
| Phase 3 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimers Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimers Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimers Disease page
150 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Alzheimers Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimers Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimers Disease condition card totals 150 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.